Video

Dr. Packiam on background of study of sequential intravesical chemo in BCG-naïve NMIBC

Author(s):

Urology Times staff

Vignesh Packiam, MD, explains the background of the study, “Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer,” which was published in the Journal of Urology. Packiam is a clinical assistant professor of Urology, Department of Urology, University of Iowa Hospitals and Clinics.

Related Videos
Related Content
UGN-101 demonstrates long-term durability in low-grade UTUC
November 26th 2024

UGN-101 demonstrates long-term durability in low-grade UTUC

Hannah Clarke
“The median DOR of 47.8 months in patients who achieved complete response with JELMYTO provides evidence of robust durability in maintaining control of low-grade UTUC over an extended period,” says Phillip Pierorazio, MD.
medical depiction of bladder cancer
May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff
In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
Cretostimogene grenadenorepvec plus nivolumab shows promise in cisplatin-ineligible MIBC
November 11th 2024

Cretostimogene grenadenorepvec plus nivolumab shows promise in cisplatin-ineligible MIBC

Hannah Clarke
"Together, the data point to the exciting potential for this combination regimen to be used to treat patients with muscle invasive bladder cancer," says Roger Li, MD.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021

Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

Urology Times staff
“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Blurred interior of hospital | Image Credit: © jakkapan - stock.adobe.com
November 6th 2024

Expert roundtables focus on upper tract urothelial carcinoma

Urology Times staff
Two case-based roundtable discussions recently covered the advancing of care for patients with low-grade upper tract urothelial carcinoma.
Study to assess performance of CxBladder test in urothelial carcinoma surveillance
November 6th 2024

Study to assess performance of CxBladder test in urothelial carcinoma surveillance

Hannah Clarke
The observational LOBSTER study has already enrolled 303 patients and collected 479 samples.
© 2024 MJH Life Sciences

All rights reserved.